MARK2P4

Across TCGA pan-cancer cohorts, MARK2P4 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MARK2P4 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MARK2P4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MARK2P4 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LIHC, ESCA, and KIRC are the cancer types where MARK2P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.051	0.716	<.001	72	view →
ESCA	OS	Tertile	All	0.198	0.872	.003	36	view →
KIRC	DFS	Tertile	IV	0.414	0.635	.033	36	view →
BLCA	DFS	Tertile	IV	0.083	0.472	<.001	27	view →
LUSC	OS	Tertile	II,III,IV	0.190	0.615	.010	27	view →
BRCA	DFS	Tertile	All	0.218	0.531	.026	12	view →
DLBC	DFS	Median	III,IV	0.140	0.917	.010	10	view →
THCA	DFS	Tertile	III,IV	0.844	0.925	.027	9	view →
GBM	OS	Tertile	All	0.379	0.173	.033	6	view →
KIRP	OS	Tertile	All	0.344	0.731	.018	6	view →
UCEC	OS	Tertile	All	0.870	0.930	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MARK2P4–LIHC (OS)

Open the LIHC breakdown →